Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Return on Sales (2019 - 2026)

ADC Therapeutics has reported Return on Sales over the past 8 years, most recently at 0.02% for Q1 2026.

  • Quarterly results put Return on Sales at 0.02% for Q1 2026, up 6.0% from a year ago — trailing twelve months through Mar 2026 was 0.02% (changed 0.0% YoY), and the annual figure for FY2021 was 0.07%, changed.
  • Return on Sales reached 0.02% in Q1 2026 per ADCT's latest filing, up from 0.03% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.0% in Q4 2022 and bottomed at 0.08% in Q1 2025.
  • Median Return on Sales over the past 5 years was 0.03% (2023), compared with a mean of 0.03%.
  • The largest annual shift saw Return on Sales skyrocketed 33bps in 2022 before it fell -5bps in 2025.
  • Over 5 years, Return on Sales stood at 0.0% in 2022, then tumbled by -1345226674bps to 0.03% in 2023, then rose by 22bps to 0.02% in 2024, then dropped by -7bps to 0.03% in 2025, then skyrocketed by 37bps to 0.02% in 2026.
  • Business Quant data shows Return on Sales for ADCT at 0.02% in Q1 2026, 0.03% in Q3 2025, and 0.03% in Q2 2025.